HIMS vs. TDOC, TGTX, LFST, NEOG, MOR, BHC, CORT, TWST, MLTX, and ACLX
Should you be buying Hims & Hers Health stock or one of its competitors? The main competitors of Hims & Hers Health include Teladoc Health (TDOC), TG Therapeutics (TGTX), LifeStance Health Group (LFST), Neogen (NEOG), MorphoSys (MOR), Bausch Health Companies (BHC), Corcept Therapeutics (CORT), Twist Bioscience (TWST), MoonLake Immunotherapeutics (MLTX), and Arcellx (ACLX). These companies are all part of the "medical" sector.
Hims & Hers Health (NYSE:HIMS) and Teladoc Health (NYSE:TDOC) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk, earnings and community ranking.
Hims & Hers Health currently has a consensus price target of $15.08, indicating a potential upside of 22.68%. Teladoc Health has a consensus price target of $18.73, indicating a potential upside of 56.76%. Given Teladoc Health's higher probable upside, analysts clearly believe Teladoc Health is more favorable than Hims & Hers Health.
Teladoc Health received 643 more outperform votes than Hims & Hers Health when rated by MarketBeat users. Likewise, 63.47% of users gave Teladoc Health an outperform vote while only 33.33% of users gave Hims & Hers Health an outperform vote.
In the previous week, Hims & Hers Health had 49 more articles in the media than Teladoc Health. MarketBeat recorded 55 mentions for Hims & Hers Health and 6 mentions for Teladoc Health. Hims & Hers Health's average media sentiment score of 0.56 beat Teladoc Health's score of 0.40 indicating that Hims & Hers Health is being referred to more favorably in the media.
Hims & Hers Health has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Teladoc Health has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.
Hims & Hers Health has higher earnings, but lower revenue than Teladoc Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Teladoc Health, indicating that it is currently the more affordable of the two stocks.
Hims & Hers Health has a net margin of -0.24% compared to Teladoc Health's net margin of -8.90%. Hims & Hers Health's return on equity of -0.70% beat Teladoc Health's return on equity.
63.5% of Hims & Hers Health shares are owned by institutional investors. Comparatively, 76.8% of Teladoc Health shares are owned by institutional investors. 31.6% of Hims & Hers Health shares are owned by insiders. Comparatively, 1.0% of Teladoc Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Hims & Hers Health beats Teladoc Health on 11 of the 17 factors compared between the two stocks.
Get Hims & Hers Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for HIMS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HIMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hims & Hers Health Competitors List
Related Companies and Tools
